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Study of the prognostic impact of multidrug resistance gene expression in the management of breast cancer in the context of
adjuvant therapy. This study involved 171 patients treated by surgery, adjuvant chemotherapy7radiotherapy7hormonal therapy
(mean follow-up: 55 months). We studied the expression of multidrug resistance gene 1 (MDR1), multidrug resistance-associated
protein (MRP1), and glutathione-S-transferase P1 (GSTP1) using a standardised, semiquantitative rt–PCR method performed on
frozen samples of breast cancer tissue. Patients were classified as presenting low or high levels of expression of these three genes.
rt-PCR values were correlated with T stage, N stage, Scarff–Bloom–Richardson (SBR) grade, age and hormonal status. The impact of
gene expression levels on 5-year disease-free survival (DFS) and overall survival (OS) was studied by univariate and multivariate Cox
analysis. No statistically significant correlation was demonstrated between MDR1, MRP1 and GSTP1 expressions. On univariate
analysis, DFS was significantly decreased in a context of low GSTP1 expression (P¼0.0005) and high SBR grade (P¼0.003), size
X5cm(P¼0.038), high T stage (P¼0.013), presence of intravascular embolus (P¼0.034), and 43Nþ (P¼0.05). On multivariate
analysis, GSTP1 expression and the presence of ER remained independent prognostic factors for DFS. GSTP1 expression did not affect
OS. The levels of MDR1 and MRP1 expression had no significant influence on DFS or OS. GSTP1 expression can be considered to be
an independent prognostic factor for DFS in patients receiving adjuvant chemotherapy for breast cancer.
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The increasing use of adjuvant chemotherapy in breast cancer,
designed to improve both disease-free survival (DFS) and overall
survival (OS), highlights the need to develop predictive tests of
tumour chemosensitivity in order to identify patients likely or
unlikely to benefit from such therapy (Bonadonna et al, 1990;
Scholl et al, 1994). Cytotoxic exposure can induce a multidrug
resistance phenotype (MDR), which can involve numerous cell
changes (Simon and Schindler, 1994). Some proteins are over-
expressed in MDR cell lines, defining a group of MDR-related
genes. In humans, P-glycoprotein (P-gp), encoded by the multi-
drug resistance gene 1 gene (MDR1) (Endicott and Ling, 1989;
Gottesman and Pastan, 1993), and multidrug resistance-related
protein MRP1, first described by Cole et al (1994), are two
membrane glycoprotein transporters belonging to the more
extensive superfamily of ATP-binding cassette (ABC) proteins
(Dean et al, 2001). More recently, other members of this family
have been implicated in multidrug resistance of breast cancer, such
as BCRP/ABCG2 and other forms (Leonessa and Clarke, 2003).
Such proteins act as energy-dependent efflux pumps capable of
expelling a large range of xenobiotics, including doxorubicin and
other cytotoxic drugs derived from natural products, out of the
cell. MRP1 can act as a transporter of glutathione conjugates
(Muller et al, 1994). Although the precise role of the glutathione
detoxification pathway in the MDR phenomenon has not yet been
fully elucidated, the isoenzymes of the glutathione-S-transferase
(GSTs), namely the subclass GSTpi (EC 2.5.1.18), have been
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sextensively reported to be overexpressed in tumour cells display-
ing the MDR phenotype (Keith et al, 1990; Buser et al, 1997;
Ferrandina et al, 1997; Frassoldati et al, 1997; Silvestrini et al, 1997;
Boku et al, 1998; Stoehlmacher et al, 2002; Oudard et al, 2002;
Cullen et al, 2003; Galimberti et al, 2003; Bennaceur-Griscelli et al,
2004). However, the role of GSTs proteins remains controversial in
the literature.
In a previous study, we used a semiquantitative rt–PCR method
to evaluate multidrug resistance gene expression in surgical breast
cancer biopsies (Lacave et al, 1998). The primary objective of the
present study was to complete this preliminary study by evaluating
the clinical impact of the expression of these genes on the
management of breast cancer in a series of 171 patients receiving
adjuvant chemotherapy.
PATIENTS, MATERIALS AND METHODS
Patients and tissue samples
This study was performed on a series of 171 surgically obtained
tumour specimens from 171 patients with stage I–III invasive
breast carcinoma, treated between April 1991 and January 2001 by
surgery (Surgical Gynecology Departments, at the La Pitie ´
Salpe ˆtrie `re and Tenon Hospitals), adjuvant chemotherapy (Med-
ical Oncology and Radiation Oncology Department, Tenon
Hospital, Paris, France), þ/  postoperative radiotherapy (Radia-
tion Oncology Department, Tenon Hospital, Paris, France), þ/ 
hormonal therapy (Medical Oncology and Radiation Oncology
Department, Tenon Hospital, Paris, France). The mean and
median ages were 54 and 52 years, respectively (range: 34–77),
and 54% of patients were postmenopausal. First-line treatment was
tumorectomy in 59.6% of patients (n¼102), and radical mastect-
omy in 40.4% of patients (n¼69) with axillary dissection in all
cases. All patients received adjuvant chemotherapy. Patients who
had received neoadjuvant chemotherapy were excluded from this
study. Radiotherapy was performed in 162 cases (94.7%), and 117
patients (68.4%) received hormonal therapy. Details of the
systemic treatments used are given in Table 1. Most patients
received anthracyclines (n¼163; 95%). The clinical and patholo-
gical characteristics of the study population are also described in
Table 1.
Histopathologic typing, Scarff–Bloom–Richardson (SBR) grad-
ing and measurement of oestrogen (ER) and progesterone (PR)
receptor levels (cutoff value: 10fmolmg
 1) were performed by
independent investigators. DNA ploidy and S-phase fraction (SPF)
were determined by DNA flow cytometry, using a standardised
method and consensus rules for interpreting the data (Chassevent
et al, 2001). Tumours containing a single cell population with a
DNA index ranging between 0.9 and 1.05 were classified as diploid,
and those with an additional cell population with a DNA index
outside the 0.9–1.05 range were defined as aneuploid. The SPF was
classified as three SPF classes, defined on the basis of terciles (33rd
and 66th percentile) after adjusting for ploidy.
rt–PCR studies
The conditions and methodological aspects of the end point rt–
PCR procedures used in this study have been previously described
in detail (Lacave et al, 1998). Although real-time PCR has been
established as the gold standard rt–PCR procedure for gene
expression studies since the end of the 1990s, most patients
described here were included in the mid-1990s, at a time when
real-time PCR was not routinely performed in the majority of
laboratories. We therefore chose to maintain the classical end
point rt–PCR method for all of these patients. Briefly, each gene of
interest was separately coamplified with its specific endogenous
standard (i.e. MDR1/b2M; MRP1/PGK; GSTp/PGK). For MDR1, the
control cell lines consisted of the drug-sensitive human epider-
moid carcinoma KB3-1 cell line and its multidrug-resistant
derivative, the KB 8-5 cell line (kindly provided by Dr Gottesman)
(Akiyama et al, 1985). The MCF7 human breast carcinoma cell line
(Soule et al, 1973) was obtained from J Robert (Institut Bergonie ´,
Bordeaux, France), and was also used to select the doxorubicin-
resistant cell line (MCF7R) used in this study. These cell lines were
used as negative and positive controls for GST P1 (GSTP1),
respectively. The IGROV cell line was obtained from J Be ´nard
(Benard et al, 1985), and was used as a negative control vs MCF7R
to check for MRP1 expression. Historically, b2M has been
Table 1 Patient characteristics
Patients (n) Patients (n)
Age (year) SBR grade
p55 102 I 28
455 69 II 73
III 67
Not available 3
Postmenopausal DNA ploidy
Yes 92 Diploid 58
No 79 Aneuploid 83
Not available 30
Clinical T stage S-phase fraction
T1 85 Low 35
T2 73 Medium 39
T3 6 High 52
T4 7 Not available 45
Histological nodal status Oestrogen receptors
N  64 Yes 111
N+ 106 No 48
Not available 1 Not available 12
Number of positive
nodes
Progesterone
receptors
o3 N+ 66 Yes 87
X3N + 3 9 N o 6 8
Not available 16
Capsular invasion Postoperative
radiotherapy
CI   116 Yes 162
CI + 5 4 N o 9
Not available 1
Histologic type Adjuvant hormonal
therapy
Ductal 139 Yes 117
Lobular 23 No 51
Others 9 Not available 3
Associated extensive in
situ carcinomas
Type of
chemotherapy
Yes 44 FEC 147
No 123 THEP VCF 15
Not available 4 FNC 7
EP 1
CMF 1
Intravascular embolus
Yes 49
No 107
Not available 15
FEC¼fluorouracil, epirubicin, cyclophosphamide; THEPVCF¼theprubicin, vincris-
tine, cyclophosphamide, fluorouracil; CMF¼cyclophosphamide, methotrexate,
fluorouracil; FNC¼fluorouracil, novantron, cyclophosphamide; EP¼epirubicin,
paclitaxel.
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sproposed for use as an internal standard for MDR1 (Beck et al,
1996) when KB cell lines are used as the control cell line (see
below). Owing to the lack of b2M expression in MCF7R, PGK was
used as the internal standard for MRP1 and GSTP1. The gene of
interest/endogenous standard ratio of test samples was expressed
in relation to the ratio found for control cell lines overexpressing
the gene tested. Calculated values were expressed in arbitrary
units. Control cell lines were also used to determine the standard
curves by serial dilutions of total RNA extracted from drug-
resistant cell lines, with total RNA extracted from their respective
drug-sensitive cell lines in order to validate and standardise the
rt–PCR conditions for optimal coamplification of the genes tested
and their respective internal control sequences. We had also
previously checked that the values obtained for control cell lines
always displayed low ranges of interassay variation (coefficient of
variation o10% in every case). Owing to the high degree of
heterogeneity observed with the rt–PCR procedures used in
previous studies to determine the expression of MDR-related
genes, no cutoff values have been clearly defined and, in
the present study, as shown in Table 2, we chose to define the
subgroups on the basis of the estimated median values of gene
expression for each gene (p or 4 the median value) (Table 2).
Statistical methods
Comparisons between the levels of expression of the three genes
studied and patient characteristics were performed using Pearson’s
w
2 test. A two-sided Po0.05 was considered significant. The DFS
was defined as the interval between first treatment and primary
failure (local and/or distant recurrence). Actuarial survival rates
were computed using the Kaplan–Meier method, and compared
using the log rank test (Kaplan and Meier, 1958). The influence of
DNA ploidy and SPF fraction on outcome, adjusted for the other
prognostic factors, was assessed by univariate and multivariate
analysis using the Cox proportional hazards regression model in a
forward stepwise procedure (Cox, 1972). The ascending method
was used for a block-by-block construction (clinical variables, and
then laboratory variables). The various variables were: (a) age at
diagnosis (p or 450 years); (b) menopausal status; (c) clinical T
stage (T1; T2; T3; T4); (d) histologic type (ductal or lobular
carcinoma); (e) histologic lymph node involvement (N ;Nþ); (f)
number of lymph nodes involved (o or X3Nþ); (g) capsular
invasion (CI ;C Iþ); (h) histologic grade (SBR I–III); (i) surgical
margins (p or 41mm); (j) vascular invasion; (k) associated
extensive (425%) in situ carcinoma; (l) intravascular and
intralymphatic embolus; (m) hormone receptor status; (n) DNA
ploidy; (o) SPF adjusted for ploidy; and expression of (p) MDR1;
(q) MRP1 and (r) GSTP1 genes, each divided into two groups
according to whether gene expression was less than or greater than
the median value of expression. As most patients received
radiotherapy (94.7%) and anthracycline-based adjuvant chemo-
therapy (95%), we deliberately excluded the type of adjuvant
therapy received by the patients from statistical analysis. The study
end points compared the levels of expression of each of the three
genes with those of the other two multidrug resistance genes, and
evaluated the influence of multidrug resistance gene expression on
5-year actuarial DFS, and overall specific survival (OS) rates.
Complete information for follow-up and secondary events were
obtained for all patients. The median follow-up from the beginning
of treatment was 56 months (range: 7–139 months).
RESULTS
Tumour characteristics and flow cytometry
Most tumours were ductal (n¼139; 81%), or lobular carcinomas
(n¼23; 13. 5%). The main characteristics of the samples are
summarised in Table 1. Most tumours were early-stage carcinomas
(T1–T2: n¼158; 92%), and were node positive (n¼106; 62%).
The hormonal status was available in 159 patients (93%). In all, 141
samples were evaluated by cytometry. A total of 58 tumours were
diploid (41%), and 83 were aneuploid (59%). Only 126 of these 141
tumour samples were available for SPF evaluation, and tumour
samples were divided into three SPF prognosis groups: tumours
with low SPF values (n¼35: 28%), intermediate SPF values
(n¼39: 31%) and high SPF values (n¼52: 41%).
RT–PCR analysis of tumour samples
Determination of MDR1 expression was available for 164 tumours
(96%). When compared with the negative KB 3.1 and positive KB
8.5 control cell lines, 68 (42%) of tumours did not express the
MDR1 gene, while 96 tumours (58%) expressed MDR1. The mean
value of the MDR1/b2M ratio was 0.05270.008 (range: 0–0.065),
with a median of 0.02.
MRP1 expression was assessed for 131 tumour samples (77%),
with a mean MRP1/PGK ratio of 0.7570.08 (range: 0–10), and a
median of 0.61. Only 10 tumours (7.6%) did not express the MRP1
gene.
GSTP1 expression was evaluated in 119 tumour samples (70%),
and only three tumours were found not to express this gene. The
mean GSTP1/PGK ratio was 0.7470.06 (range: 0–4.6) with a
median of 0.63.
Table 3 reports the levels of expression of the three genes in
relation to the clinical and laboratory characteristics of patients
and samples. No statistically significant difference in the expres-
sion of any of the MDR-related genes was observed between any of
the subgroups, apart from tumours with negative ER or PR, in
which GSTP1 expression was significantly higher.
When the values were analysed as continuous values, no
statistically significant correlation was found between MDR1,
MRP1 and GSTP1 expression.
Patient outcome
Nine (5.5%) patients developed local recurrence after a mean
interval of 27.5 months (range: 2–49 months), three (1.7%)
patients developed a regional axillary relapse (mean interval: 29
months, range: 9–53 months), and 24 patients (14%) developed
distant metastasis after a mean interval of 36 months (range: 3–83
months). In all, 18 patients had died at the endpoint date of this
analysis: 17 from cancer (10%) and one from another cause. A total
of 16 (9.3%) patients developed a second cancer (breast and/or
another primary tumour).
The 5-year DFS rate was 79.7% (73.3; [73.3–86.6]) in the
overall population, 82% (75.6; [71.7; 93.7]) among node-negative
patients, and 79.3% (74.2; [71.5–87.9]) among node-positive
patients (P¼0.38). The 5-year specific survival was 89.7% (72.7;
[84.5–95.2]) in the overall population, 93.3% (73.9; [85.9–1])
among node-negative patients, and 88.3% (73.6; [81.6–95.6])
among node-positive patients (P¼0.26).
Prognostic impact of multidrug resistance genes
In the overall population, univariate Cox analysis showed a better
5-year DFS rate in the group of patients with high GSTP1
expression than in the group with low GSTP1 expression
(95.470.03% [89.2–100] versus 71.970.06% [60.4–85.6];
HR¼0.33; P¼0.0005, Figure 1). Other factors found to be
significantly correlated with DFS on univariate analysis were SBR
grade (P¼0.039), T stage (P¼0.013), more than three positive
nodes (P¼0.05), and presence of intravascular and intralymphatic
embolus (P¼0.034) (Table 4). Expression of the other two
multidrug resistance genes, MDR1 and MRP1, did not influence
5-year DFS.
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laboratory data were available for 90 patients. In the overall
population, ER receptor status and subgroups based on GSTP1
expression were shown to be independent predictors for DFS
(P¼0.002 and 0.011, respectively).
On univariate analysis, only two factors statistically influenced
the 5-year OS rate: SBR grade (P¼0.028), and clinical lymph node
status (N0 vs N1, P¼0.039). Expression of the three multidrug
resistance genes studied did not influence the 5-year OS. Cox
multivariate analysis did not demonstrate any factor indepen-
dently correlated with 5-year OS.
DISCUSSION
The increasing use of chemotherapy in breast cancer has led
physicians to develop accurate and reliable tests to identify MDR
determinants in clinical studies. However, very limited data are
Table 2 Definition of subgroups according to the median value of gene
expression
Gene expression
Low High
MDR1 p2% (n¼93) 42% (n¼72)
MRP1 p61.7% (n¼105) 461.7% (n¼66)
GSTP1 p63% (n¼61) 463% (n¼59)
Table 3 MDR phenotype according to patient and tumor characteristics
MDR1 MRP GSTp
Age (year)
a
p55 5.8671.12 0.288 83.7977.77 0.745 70.3716.91 0.459
455 4.1870.95 63.8276.38 80.1711.22
Postmenopausal
Yes 3.9770.75 0.09 70.9677.85 0.976 81.379.44 0.222
No 6.5971.42 81.78718.15 65.1878.44
Clinical T stage
T1 4.9571.04 0.534 104.21717.93 0.029 77.179.92 0.362
T2 4.8371.09 54.7476.1 69.5177.19
T3 11.279.49 35.53715.57 123.8784.76
T4 7.2575.1 43.5718.28 49.5720.41
Histologic type
b
Ductal carcinomas 5.6170.93 0.289 81.82710.68 0.284 73.0476.9 0.524
Lobular carcinomas 3.3271.38 53.08711.93 85.31722.6
SBR grade
c
SBRI 5.1372.16 0.804 71.83713.7 0.933 89.63721.75 0.622
SBRII 4.7470.96 82.37719.41 66.478.86
SBRIII 5.8771.42 70.0277.82 76.8379.31
Histologic nodal status
N  6.1871.58 0.326 79.67719.59 0.465 85.15710.0 0.230
N+ 4.5970.8 72.0477.54 68.9178.56
Intravascular embolism
Yes 5.2871.39 0.684 73.66711.83 0.963 57.07710.68 0.08
No 4.6370.87 75.16712.53 82.778.4
Associated extensive in situ carcinoma
Yes 6.0471.58 0.56 77.04712.9 0.56 71.32713.25 0.7
No 4.9870.91 74.84711.31 77.3377.71
Oestrogen receptor status
Negative 7.4572.04 0.08 60.6775.16 99.09712.3
Positive 4.2970.78 79.31712.56 0.59 65.3978.05 0.028
Progesterone receptor status
Negative 5.5171.52 0.835 67.9978.29 0.571 87.0478.7 0.038
Positive 5.1570.95 79.43716.72 59.9979.47
DNA ploidy
Diploid 5.4571.57 0.735 69.63710.44 0.164 68.19711.26 0.298
Aneuploid 6.1071.15 61.5175.85 84.3179.84
S-phase fraction
Low 5.171.43 0.312 75.66711.11 0.580 84.32715.63 0.719
Medium 4.5271.59 71.79713.61 81.72713.68
High 7.9571.96 61.2976.4 70.877.4
aPatient’s age.
bOther histologic types were excluded.
cSBR: Scarff–Bloom–Richardson index. Values are expressed as mean7s.e. of RNA levels of MDR1, MRP1 and GSTP1 rt–
PCR products, expressed as a percentage of control cell lines. One-way analysis of variance was used to compare these variables.
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savailable in the literature in this field and the precise mechanism of
action, the relationship between multidrug resistance genes, and
their clinical impact on the outcome of patients with breast cancer
remain unclear, as published results have been discordant (Keith
et al, 1990; Buser et al, 1997; Frassoldati et al, 1997; Silvestrini et al,
1997; Trock et al, 1997; Ferrero et al, 2000; Leonessa and Clarke,
2003). Few data are available concerning the impact of multidrug
resistance genes on the clinical outcome of patients treated for
breast cancer. This study was mainly designed to evaluate the
clinical impact (DFS and OS) of MDR1, MRP1 and GSTP1 gene
expression on the management of patients with breast cancer
treated by adjuvant chemotherapy.
When the values were considered as continuous values,
correlation studies did not reveal any statistically significant
correlation between MDR1, MRP1, and GSTP1 expressions. In the
previous study, published in 1998, based on a series of 74 patients,
we observed a significant positive correlation between MRP1 and
GSTpi expression (Lacave et al, 1998). This correlation was not
confirmed in the present study, possibly because of a more
scattered distribution of expression levels. Although GSH has been
demonstrated to be necessary for MRP1-mediated cellular efflux of
certain natural substances (Rappa et al, 1997) and although in
vitro detoxification of anticancer agents involves a combined
action of GSTs and MRPs (Morrow et al, 1998; O’Brien et al, 2000;
Depeille et al, 2004; Depeille et al, 2005), a clear-cut correlation
between MRP1 and GSTP1 expression has yet to be established in
the clinical setting.
In this series, the 5-year DFS and OS were not influenced by the
expression of either MDR1 or MRP1. In a series of 85 node-positive
breast cancer patients receiving anthracycline-based adjuvant
therapy, Ferrero et al (2000) did not find any significant influence
of MDR1 and MRP1 on progression-free or overall specific
survival, and Kanzaki et al (2001) did not observe any correlation
between MRP1 mRNA expression and relapse after doxorubicin
adjuvant therapy. In contrast, in a series of 59 breast cancer
patients, Burger et al (2003) reported a clear link between RNA
expression of lung resistance-related protein and MDR1, and
progression-free survival, but this series included only advanced
cases. In a recent publication based on 104 patients treated for
breast cancer, higher MDR1/P-gp expression was associated with a
statistically significant shorter OS and progression-free time, but
the authors used a method based on immunohistochemical
reactions using monoclonal antibodies (Surowiak et al, 2005). In
a study of 27 patients, the risk of relapse in the 10 years following
adjuvant chemotherapy was higher in patients whose primary
tumours expressed higher levels of MRP1 mRNA (Ito et al, 1998).
Heterogeneous results are a common feature of studies evaluating
the expression and prognostic role of this gene, mainly due to both
methodological and biological factors, and the prognostic impact
of these two genes on DFS or OS remains to be established
(Leonessa and Clarke, 2003).
The main result emerging from this study is that GSTP1
expression can be taken into account in the management of breast
cancer patients receiving adjuvant chemotherapy.
In this study, we clearly demonstrated, on both univariate and
multivariate Cox analysis, that subgroups based on GSTP1
expression were shown to be independent predictors of DFS, with
a better 5-year DFS rate in the group of patients with high GSTP1
expression than in the group with low GSTP1 expression. This
finding supports the results of previous studies concerning various
type of tumours (Goasguen et al, 1996; Buser et al, 1997; Howells
et al, 1998; Kearns et al, 2001). For example, Buser et al (1997), in a
series of 89 women with untreated breast cancer, found that high
levels of Gst and Gpx activities were associated with favourable
clinical characteristics and a good prognosis, whereas low levels of
Gst activity were associated with more aggressive or more
advanced disease, although the results did not reach the limit of
statistical significance. However, the results of our study are
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Figure 1 5-year disease-free survival according to level of GSTP1
expression.
Table 4 5-year disease-free survival rates and Cox univariate analysis
n pts 5-year DFS (7s.e.) (%) [CI] P;H R
GSTp 0.0005; 0.33
Low expression 60 71.9 (76.3) [60.4–85.6]
High expression 60 95.4 (73.3) [89.2–100]
NA 51
T Stage 0.013; 2.48
T1 85 87.4 (73.7) [80.4–95.1]
T2 73 77 (76) [66.1–89.8]
T3 6 25.5 (726.3) [4–100]
T4 7 46.8 (718.2) [21.9–100]
Intravascular embolus 0.034; 1.53
Yes 49 70.4 (77) [57.9–85.7]
No 107 86.9 (73.7) [80.1–94.2]
SBR grade 0.039; 1.75
SBRI 28 100
SBRII 73 74.6 (75.6) [64.4–86.5]
SBRIII 67 77.2 (75.4) [67.2–88.7]
43N + 0.05; 2.17
Yes 39 71.3 (77.3) [58.2–87.2]
No 66 83 (73.7) [75.9–90.7]
NA¼not available; N Pts¼number of patients; SBR¼Scarff–Bloom–Richardson;
T¼T stage according to TNM AJCC 2002 classification; [CI]¼confidence interval;
HR¼hazard ratio. 43N+¼more than three positive nodes involved.
Table 5 Cox multivariate analysis for 5-year disease-free survival
Overall population (n¼90)
Relative risk (s.e.) P
Oestrogen receptor status 0.066 (0.876) 0.002
GST P1 level expression (p vs 463%) 0.302 (0.469) 0.011
Model for overall population included the following factors (factors with a P-value
o0.2 using univariate analysis): SBR grade, T stage, clinical and histologic node
involvement, number of lymph nodes involved (o or X3 N+), capsular invasion,
presence of intravascular or intratumoral embolus, presence of intraductal or
intralobular extensive carcinoma, oestrogen receptor status, MDR1 and GSTP1 gene
expression.
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study, all patients had received adjuvant chemotherapy, whereas in
Buser’s study, only a small minority of patients had received
adjuvant chemotherapy. The mean age of the population was also
considerably higher in the study by Buser et al. This might explain
why GSTP1 was found to be a significant prognostic factor on both
univariate and multivariate analysis.
The precise molecular mechanism responsible for this phenom-
enon is unclear. As GSTP1 is the major GSTs consistently
expressed in both normal and tumour breast tissue (Forester,
Carcinogenesis 1990; 11: 2163–2170), it can be hypothesised that
low GSTP1 expression would reduce the global activity of GSTs,
and consequently reduce glutathione (GSH) consumption in GST-
catalysed reactions, thereby leading to higher levels of GSH, which
would block apoptosis and promote proliferation of tumour cells.
This hypothesis was first proposed by Kearns et al (2001), who
reported an association between elevated GSH levels in leukaemia
cells and an increased risk of relapse in childhood acute lymphoid
leukaemia. Morales et al (2005) recently confirmed these results,
by showing that intracellular glutathione levels determine cell
sensitivity to drug-induced apoptosis. It has also been demon-
strated that intracellular GSH depletion of human oral squamous
cell carcinoma by inorganic selenium compounds may cause
caspase-9-mediated apoptosis (Takahashi et al, 2005).
A possible explanation for the increased DFS in patients with
high levels of GSTP1 expression could involve the role of GSTP1 on
cell proliferation. GSTP1 has been identified as a modulator of cell
signaling, by interacting with and inhibiting c-Jun N terminal
kinase (JNK) (Adler et al, 1999; Elsby et al, 2003) implicated in the
control of cell proliferation (Timokhina et al, 1998; Tournier et al,
2000) and transformation (Raitano et al, 1995; Xiao and Lang,
2000). These results are consistent with the work by Ruscoe
et al (2001), showing that GST-depleted cells, which exhibited a
higher JNK activity, proliferated faster than their wild-type
counterparts.
An hypothesis can be proposed to explain the molecular
mechanisms responsible for higher levels of expression of GSTP1
in patients with better DFS, as the very variable levels of expression
of GSTP1 cannot be explained by the presence of variant genotypes
previously implicated in the pathogenesis of breast cancer in
patients treated with chemotherapy (Yang et al, Cancer 2005; 103:
52–58), as these variants are mainly related to variations of
enzyme catalytic activity (Sweeney, Cancer Res 2000; 60: 5621–
5624). Complementary studies are currently underway to test this
hypothesis, which was not included in the initial design of our
study. Altered DNA methylation, related to the fundamental role of
epigenetic events in cancer (Jones and Baylin, 2002; Verma et al,
2004) now constitutes a growing field of clinical investigation in
cancer (Das and Singal, 2004) and could possibly explain variable
levels of GSTP1 expression in our patients. Altered DNA
methylation has been well documented in breast cancer (for
review see Widschwendter and Jones, 2002). In particular,
inactivation of GSTP1 by promoter hypermethylation was initially
reported to be frequent in renal carcinoma and in about 30% of
primary breast cancers by Esteller et al (1998). Hypermethylation
of CpG dinucleotides at the 50 transcriptional regulatory region has
been shown to be sufficient to inhibit GSTP1 transcription in the
MCF-7 breast cancer cell line when mediated by the methyl-CpG-
binding domain (MBD) protein MBD2 (Lin and Nelson, 2003).
Jhaveri and Morrow (1998) previously showed that the GSTP1 CpG
island is hypermethylated in ER-positive, GSTP1-nonexpressing
MCF-7, but is undermethylated in ER-negative, GSTP1-expressing
cell lines. Note that, in our study, both ER- and PR-negative
patients exhibited higher levels of GSTP1 expression. In a recent
study, Shinozaki showed that hypermethylation of GSTP1 was
significantly associated with macroscopic sentinel lymph node
metastasis compared to patients with microscopic or no sentinel
lymph node (Shinozaki et al, 2005).
Most authors have studied the relevance of MDR phenotype as a
predictive test for breast cancer response in patients treated by
neoadjuvant chemotherapy, and have found that MDR phenotype
is indeed a relevant tool for monitoring breast cancer response to
this treatment (Chevillard et al, 1996; Trock et al, 1997; Burger
et al, 2003). In this study, we deliberately excluded patients who
had received neoadjuvant chemotherapy in order to obtain a
homogeneous population. This subject will be further developed in
a study to be published subsequently.
In conclusion, our findings suggest that a low level of GSTP1
gene expression is an independent predictive factor of poor 5-year
DFS in patients treated by adjuvant chemotherapy for breast
cancer. MDR1, MRP1 did not show any significant influence on the
prognosis of these patients.
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